|
UBE2A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62447832963153E-12 |
| Normal-vs-Stage2 |
1.82566999999967E-05 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
5.15509968046501E-10 |
| Stage1-vs-Stage2 |
5.619700E-02 |
| Stage1-vs-Stage3 |
1.916400E-01 |
| Stage1-vs-Stage4 |
3.494600E-01 |
| Stage2-vs-Stage3 |
2.324400E-01 |
| Stage2-vs-Stage4 |
2.671600E-02 |
| Stage3-vs-Stage4 |
1.004040E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
1.49329999998837E-06 |
| Normal-vs-Asian |
6.61170007631995E-10 |
| Caucasian-vs-AfricanAmerican |
1.538000E-01 |
| Caucasian-vs-Asian |
1.840190E-01 |
| AfricanAmerican-vs-Asian |
7.386800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62447832963153E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
3.023200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
<1E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(61-80Yrs) |
4.04232203266019E-13 |
| Normal-vs-Age(81-100Yrs) |
4.040600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.002120E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.611670E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.439200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.695400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.376400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.836000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.621400E-01 |
| Classical-VS-Follicular |
5.755200E-01 |
| Classical-VS-Other |
3.725600E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
3.063800E-01 |
| Tall-VS-Other |
2.035800E-01 |
| Tall-VS-Normal |
3.2621999546123E-09 |
| Follicular-VS-Other |
6.565000E-01 |
| Follicular-VS-Normal |
3.471799958632E-09 |
| Other-VS-Normal |
3.306400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62447832963153E-12 |
| Normal-vs-N1 |
2.69069999614402E-09 |
| N0-vs-N1 |
9.527800E-01 |
|
|
